Re-mark
Angelman Syndrome Market Landscape: Latest Late-Stage Therapies Failures The total Angelman syndrome prevalent cases in the 7MM (the US, EU5 (the UK, Germany, Spain, Italy and France) and Japan) was estimated to be 57,716 in 2017. However, many cases go undetected or underdiagnosed since, the diagnosis is usually based on the behavioural phenotype, particularly combinations of movement disorder, absent speech, and happy demeanor. To tackle the situation, several pharmaceutical and biotech companies in the Angelman syndrome market are exploring the novel curative approaches. With high hopes from GeneTx’s therapy after the doors were closed for Ovid, Roche and Sarepta/StrideBio, the AS market is still a risky affair. Of all the Angelman syndrome pipeline therapies, the most touted treatment, Gaboxadol, a product of Ovid Therapeutics, failed in late-stage Phase III trials. Thus, it is yet to see which therapy wins the race in the AS market.
You may like
Matte Visiting Cards
#MatteVisitingCards, #MatteFinish, #ElegantBusinessCards, #SmoothTouch, #PremiumQuality, #CustomMatteCards, #ModernDesign
Glossy Business Cards
#GlossyBusinessCards, #HighGlossFinish, #ShinyBusinessCards, #LuxuryVisitingCards, #PremiumPrinting, #ProfessionalDesign, #VibrantColors
Eco-Friendly Business Card
#EcoFriendlyBusinessCards, #SustainableDesign, #RecycledPaperCards, #GreenPrinting, #EcoBranding, #BiodegradableCards, #EnvironmentFriendly